CytoDyn to Host Investor Webcast
CytoDyn announced an investor webcast on October 19, 2026, at 1 p.m. PT to provide a corporate and clinical update on leronlimab, its CCR5-targeting monoclonal antibody in oncology. The webcast will feature CEO Dr. Jacob Lalezari and CFO Robert Hoffman, plus representatives from City of Hope and Natera discussing their strategic collaboration and early ctDNA observations from the CLOVER study.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.